Diligence memo · auto-generated · as of July 2, 2026

Tabula Rasa HealthCare, Inc.

Tabula Rasa HealthCare, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Tabula Rasa HealthCare, Inc. operates in Healthtech, based in Moorestown.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Tabula Rasa HealthCare, Inc. has raised $109M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $53M on 2017-09-06.

Most recent recorded round closed around 2020-10-05.

Valuation (modeled)modeled

Provath models Tabula Rasa HealthCare, Inc. at approximately $573M (range $88M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.53× the median modeled value of Series C Healthtech companies in 2019–2021 (33 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 5.7 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 96% of Healthtech peers (2138 compared).

Modeled value ranks above 94% of those peers.

Closest niche peers: Virta Health Corp., Fresenius Medical Care Voorhees, LLC, Clear Health Pass Holdings LLC, Zealth, Inc., Jawbone Health Hub, Inc..

Peoplefiled

15 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.